StemCells Inc (STEM)

6.03
0.28 4.44
NASDAQ : Health Care
Prev Close 6.31
Open 6.25
Day Low/High 5.83 / 6.38
52 Wk Low/High 2.97 / 48.60
Volume 462.78K
Avg Volume 118.20K
Exchange NASDAQ
Shares Outstanding 1.81M
Market Cap 20.81M
EPS -4.60
Div & Yield N.A. (N.A)

Latest News

IIROC Trading Halt - STEM

IIROC Trading Halt - STEM

VANCOUVER, Oct. 10, 2018 /CNW/ - The following issues have been halted by IIROC: Company: Stem Holdings Inc.

These 5 Stocks Under $10 Could Make You a Lot of Money

These 5 Stocks Under $10 Could Make You a Lot of Money

Here's a technical look at how to trade several under-$10 stocks triggering breakout trades.

StemCells, Inc. Encourages Stockholders To Return Proxies Approving The Microbot Merger By November 14, 2016

StemCells, Inc. Encourages Stockholders To Return Proxies Approving The Microbot Merger By November 14, 2016

Four of Five Proposals Approved at Company's 2016 Special Stockholder Meeting

StemCells (STEM) Stock Plummets, CEO, CFO Resign

StemCells (STEM) Stock Plummets, CEO, CFO Resign

StemCells (STEM) CEO Ian Massey and CFO Gregory Schiffman announced their resignations as the company announced its planned merger with Microbot Medical.

One Reason Why StemCells (STEM) Stock Is Down Today

One Reason Why StemCells (STEM) Stock Is Down Today

StemCells (STEM) said in an SEC filing that it will accept warrant exercises from shareholders to purchase common stock at a reduced price.

Closing Bell: Crude Oil Rallies Into Day Four; U.S. Stocks Fall From Records

Closing Bell: Crude Oil Rallies Into Day Four; U.S. Stocks Fall From Records

Worries over the next rate hike superseded joy over the four-day rally in crude oil, sending stocks into the red and away from their record highs.

StemCells (STEM) Stock Skyrockets on Microbot Medical Merger

StemCells (STEM) Stock Skyrockets on Microbot Medical Merger

StemCells (STEM) has announced a merger with Microbot Medical to develop robotics-based medical devices.

StemCells, Inc. And Microbot Medical Ltd. Announce Strategic Merger

StemCells, Inc. And Microbot Medical Ltd. Announce Strategic Merger

Companies Plan to Pursue Development of Robotics Based Medical Devices for the Treatment of Cerebrospinal Fluid and Gastrointestinal Disorders, as Well as Other Conditions

StemCells, Inc. Announces Termination Of Phase II Pathway Study Following Review Of Data

StemCells, Inc. Announces Termination Of Phase II Pathway Study Following Review Of Data

Company to Commence Orderly Wind Down of Operations

StemCells, Inc. Presents Interim Results From Its Phase II Pathway Study In Chronic Cervical Spinal Cord Injury At ASIA Annual Meeting

StemCells, Inc. Presents Interim Results From Its Phase II Pathway Study In Chronic Cervical Spinal Cord Injury At ASIA Annual Meeting

Final Results for the First Six Patients to be Released Later this Quarter

StemCells, Inc. Reports Fourth Quarter And Full Year 2015 Financial Results And Provides Business Update

StemCells, Inc. Reports Fourth Quarter And Full Year 2015 Financial Results And Provides Business Update

Conference Call to be Hosted March 24, 2016, at 5:00 a.m. Pacific Daylight Time (8:00 a.m. Eastern Daylight Time)

StemCells, Inc. CEO Martin McGlynn Passes Baton To President And COO Ian Massey

StemCells, Inc. CEO Martin McGlynn Passes Baton To President And COO Ian Massey

Experienced Biotech Leader to Become Next Chief Executive Officer

StemCells, Inc. To Participate At The 8th Annual Biotech Showcase Investor Conference

StemCells, Inc. To Participate At The 8th Annual Biotech Showcase Investor Conference

Management Will Present an Update on the Company's Programs, Pipeline and Operations

StemCells, Inc. Announces Strategic Realignment

StemCells, Inc. Announces Strategic Realignment

Prioritizes Spinal Cord Injury Program to Reduce Cash Needs and Expedite Progress to Pivotal Data

StemCells, Inc. Interim Trial Data Show Motor Improvement In Patients With Cervical Spinal Cord Injury

StemCells, Inc. Interim Trial Data Show Motor Improvement In Patients With Cervical Spinal Cord Injury

Positive Six-Month Results, With Gains in Both Strength and Motor Function, for the First Cohort in the Phase II Pathway Study